BeOne Medicines Ltd.ONC
Oncology8 cited findings · profile updated 2026-08-20
376.86 USDnot live — refreshed daily
About BeOne Medicines Ltd.
BeOne Medicines Ltd. (ONC) is an oncology research site. The company's drug Tevimbra is being investigated for a new therapeutic indication: first-line treatment of adult patients with recurrent, not amenable to curative surgery or radiotherapy or metastatic nasopharyngeal carcinoma (NPC). This is supported by the Phase 3, Asia-only, randomised, double-blind, placebo-controlled study BGB-A317-309 (study 309), which compares Tevimbra combined with gemcitabine plus cisplatin (GC) versus placebo combined with GC as 1L treatment. The company also has a PDUFA date in 2024 for Brukinsa.
Compiled from the cited findings below — figures are as stated in each company's published technical reports and filings.
Key figures — cited
| Variation type | Type II | BeOne Medicines Ltd. — Tevimbra EMA EPAR variation assessment report (, p.134 |
| PDUFA date | 2024 | BeOne Medicines Ltd. — Brukinsa FDA Review (NDA/BLA 213217, 2024), p.19 |
Key projects
- Tevimbra (first-line treatment of adult patients with recurrent, not amenable to curative surgery or radiotherapy or metastatic nasopharyngeal carcinoma (NPC))
A Type II variation is being assessed for Tevimbra for a new therapeutic indication: first-line treatment of adult patients with recurrent, not amenable to curative surgery or radiotherapy or metastatic nasopharyngeal carcinoma (NPC).
- Brukinsa — US
Brukinsa has a PDUFA date in 2024.
Every figure cites its source document. Prices refresh daily, not live. Informational only — not investment advice. Explore the Oncology research library →